Our Mission

At OncoFirm™ Diagnostics, It’s Personal.

Cancer is more than a disease—it is a profoundly personal experience. Every member of our team has been affected by cancer through a parent, sibling, spouse, child, friend, or colleague. We understand the uncertainty of waiting for answers and the importance of having them as early as possible.

That shared experience inspires our purpose and shapes everything we do.

• ONCOFIRM
• ONCOFIRM DIAGNOSTICS
• ONCOFIRM CANCER BIOMARKER ATLAS
• ONCOFIRM KNOWLEDGE CENTER
• ONCOFIRM RAPID CANCER TESTS
• ONCOFIRM FLUORESCENT LATERAL FLOW PLATFORM

At OncoFirm™ Diagnostics, our mission is to transform cancer detection through innovative biomarker discovery and next-generation in vitro diagnostic (IVD) technologies that enable earlier, faster, and more accurate diagnosis.

Grounded in current scientific evidence and driven by recent advances in molecular diagnostics, immunodiagnostics, precision oncology, and translational medicine, we develop highly sensitive diagnostic platforms that help clinicians detect cancer when treatment is most effective. We believe that every improvement in diagnostic performance has the potential to improve clinical decision-making, expand treatment options, and ultimately save lives.

Our research focuses on the discovery, validation, and clinical translation of cancer-associated biomarkers that can be integrated into affordable, scalable point-of-care and laboratory diagnostic solutions. By combining proprietary particle chemistry, advanced signal amplification technologies, and digital diagnostic platforms, we are advancing a new generation of rapid diagnostics designed to improve analytical sensitivity while maintaining speed, simplicity, and affordability.

Our mission extends beyond technology. We are committed to accelerating the adoption of evidence-based diagnostics that improve healthcare delivery across diverse clinical settings.

Human Healthcare

We develop innovative rapid cancer diagnostics that support physicians, hospitals, cancer centers, and diagnostic laboratories by providing clinically meaningful results in minutes rather than days. Earlier detection enables earlier intervention, more personalized treatment decisions, and improved patient outcomes.

Veterinary Oncology

Cancer affects millions of companion animals each year. We are equally committed to advancing veterinary diagnostics through affordable point-of-care cancer screening technologies that empower veterinarians to identify disease earlier and improve the quality and longevity of life for the animals families cherish.

Our Scientific Commitment

Our work is guided by four core principles:

• Scientific Excellence — Advancing biomarker discovery through rigorous research, analytical validation, and clinical evidence.

• Innovation in IVD — Developing next-generation in vitro diagnostic technologies that redefine the performance of rapid diagnostic testing.

• Accessibility — Making high-performance diagnostics available across hospitals, clinics, laboratories, veterinary practices, and underserved healthcare environments.

• Collaboration — Partnering with healthcare providers, academic institutions, biotechnology companies, and research organizations to accelerate scientific discovery and clinical translation.

Our Vision

We envision a future where highly sensitive biomarker-based diagnostics become the standard of care for cancer screening and disease monitoring.

Through continuous innovation in biomarker science, immunodiagnostics, digital diagnostics, and point-of-care testing, OncoFirm™ Diagnostics is working to make early cancer detection faster, more accessible, and more reliable for patients and healthcare professionals around the world.

Because every earlier diagnosis represents an opportunity for better treatment, improved outcomes, and more lives saved.